What is it about?
Based on the trial evidence for adult patients with proliferative lupus nephritis, mycophenolate mofetil is more effective than other immunosuppressive therapies in a relatively long (2 years) treatment period.
Featured Image
Why is it important?
Considering also the better safety profile associated with mycophenolate mofetil, this therapy may be selected as the first choice for proliferative lupus nephritis.
Perspectives
Trial evidence shows that mycophenolate mofetil is more effective in a relatively long treatment period of about 2 years for proliferative lupus nephritis than other immunosuppressive therapies.
Mr Simon Y. Tian
University of Toronto
Read the Original
This page is a summary of: Immunosuppressive Therapies for the Maintenance Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis, The Journal of Rheumatology, June 2015, The Journal of Rheumatology,
DOI: 10.3899/jrheum.141650.
You can read the full text:
Contributors
The following have contributed to this page
